Michaelson Diagnostics Limited develops imaging products using a technology called Multi-Beam Optical Coherence Tomography (OCT).  This technology enables in-vivo capture, visualisation and measurement of histopathology details that are too small to be seen with ultrasound, and too deep for conventional microscopy.  It provides a unique way for a dermatologist to see detailsof a skin lesion quickly and non-invasively, so that earlier, more accurate, lower cost and less invasive treatments with a better clinical outcome can be applied and the progress of the treatment easily monitored.  The Company's current VivoSight OCT scanner with hand-held probe is CE approved in Europe and has 510(k) FDA clearance in the USA for clinical use in dermatology clinics.